April 2026
M	T	W	T	F	S	S
	1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30

Heghine Khachatryan: Rethinking First-Line Therapy for Iron Deficiency Anemia in Women

Heghine Khachatryan/LinkedIn

Jan 11, 2026, 09:48

Heghine Khachatryan: Rethinking First-Line Therapy for Iron Deficiency Anemia in Women

Heghine Khachatryan, Editor-in-Chief at Hemostasis Today, shared a post by American Society of Hematology on LinkedIn:

“Iron deficiency anemia in women – especially those with heavy menstrual bleeding – continues to be underdiagnosed and undertreated worldwide.

New evidence published in Blood Advances and highlighted by the American Society of Hematology demonstrates that single-dose intravenous iron dextran is a cost-effective first-line therapy for this population.

When evaluated across a woman’s reproductive lifetime, IV iron provides:

superior clinical value
improved quality-of-life outcomes
better long-term cost-effectiveness

compared with oral iron, which is still widely used as first-line treatment.

These findings should prompt us to reconsider current treatment algorithms and move toward more patient-centered, evidence-based care for women with iron deficiency anemia.”

Quoting American Society of Hematology’s post, adding:

“Iron deficiency anemia remains underdiagnosed and undertreated in women, particularly those with heavy menstrual bleeding.

According to new research published in Blood Advances, single-dose IV iron dextran is the cost-effective first-line therapy for this population. When evaluated across a woman’s reproductive lifetime, IV iron provided superior value and quality-of-life benefits compared with oral iron, which is currently the more predominant first-line treatment for these patients.

Learn more.”

Heghine Khachatryan